Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Exploring the Efficacy of Combining Desmopressin and Bevacizumab as an Antiangiogenic Approach for Osteosarcoma Treatment

  • By

  • Luisina María Solernó

  • Candela Llavona

  • Zahira Yasmine Saud

  • Mariana Carolina Onassis

  • María Florencia Gottardo

  • Martín Manuel Ledesma

  • Daniel Fernando Alonso

  • Juan Garona

  • July 1, 2026

Share

Original Source(s)

Related Content